Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Published Date: 13 Oct 2026

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Read Full News

Latest News

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Todays Updates

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Todays Updates

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Latest News

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

News All Time

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids Elizabeth Spencer, MD, MS

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

How FDA Approval of SimpleScreen CRC Could Expand Colorectal Cancer Screening With Mark Fendrick, MD Mark Fendrick, MD

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 years and older.

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

6 Gastroenterology Headlines You Missed in August 2026 Alex Hillenbrand

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

43% Lower Mortality Seen in Colorectal Screening Participants Johannes Blom, MD, PhD

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer Alex Hillenbrand

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

TEV '408 Meets Primary Endpoint in Celiac Trial Alex Hillenbrand

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

C Diff Resistance to Bacitracin Reveals Potential Drug Target

C Diff Resistance to Bacitracin Reveals Potential Drug Target

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

Recommended News For You

Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests

Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

Prostate cancer detection with PET CT and PET MRI is comparable.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

A radiotheranostic approach designed to combat aggressive cancers

Report suggests a big improvement in lung cancer survival

Recommended Articles For You

A Closer Look at the Effects of Sickle Cell on Eyesight 

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage 

The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies 

Targeted Degraders for Lymphoma: Mechanisms, Clinical Implications, and Emerging Therapies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sports for girls are frequently abandoned due to uniform issues.

2.

November 2023, Medical Bulletin 04/.

3.

Induction Immunotherapy Has Durable Survival Benefit in LACC

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Smartphone App Detects Eye Cancers From Photos

1.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

2.

Exercise Capacity During Cancer Recovery: Clinical Evidence, Mechanisms, and Practical Implications

3.

From Bruises to Blood Clots: Everything You Need to Know about Hematoma 

4.

RNA-Targeting Chimeras in Cancer: Mechanisms, Clinical Advances, and Future Directions

5.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

3.

Importance of Cancer Screening and Early Detection

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

5.

Navigating the Complexities of Ph Negative ALL - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot